ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.86
-0.21%
Dow Jones
38,589.16
-0.15%
Gold vs US Dollar
2,333.015
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,623.43
0.65%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. GeoVax Labs Inc (GOVXW)

  7. GeoVax Labs Inc (GOVXW) News

GeoVax Labs (GOVXW)

GeoVax Labs Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GOVXW
DateTimeSourceHeadlineSymbolCompany
07/06/202421:01Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:GOVXWGeoVax Labs Inc
24/05/202421:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GOVXWGeoVax Labs Inc
23/05/202421:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GOVXWGeoVax Labs Inc
21/05/202422:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GOVXWGeoVax Labs Inc
21/05/202417:32Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GOVXWGeoVax Labs Inc
15/05/202421:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GOVXWGeoVax Labs Inc
14/05/202422:09Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:GOVXWGeoVax Labs Inc
14/05/202422:09Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:GOVXWGeoVax Labs Inc
14/05/202422:08Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:GOVXWGeoVax Labs Inc
14/05/202422:07Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:GOVXWGeoVax Labs Inc
14/05/202421:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GOVXWGeoVax Labs Inc
04/04/202417:30GlobeNewswire Inc.GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 VaccineNASDAQ:GOVXWGeoVax Labs Inc
28/03/202413:00GlobeNewswire Inc.GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine CongressNASDAQ:GOVXWGeoVax Labs Inc
12/03/202413:00GlobeNewswire Inc.GeoVax to Present at the 36th Annual Roth ConferenceNASDAQ:GOVXWGeoVax Labs Inc
06/03/202414:00GlobeNewswire Inc.GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing SystemNASDAQ:GOVXWGeoVax Labs Inc
29/02/202421:00GlobeNewswire Inc.GeoVax Reports 2023 Year-End Financial Results and Provides Business UpdateNASDAQ:GOVXWGeoVax Labs Inc
22/02/202414:00GlobeNewswire Inc.GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024NASDAQ:GOVXWGeoVax Labs Inc
19/02/202414:00GlobeNewswire Inc.GeoVax to Present at the 2024 BIO CEO & Investor ConferenceNASDAQ:GOVXWGeoVax Labs Inc
13/02/202414:00GlobeNewswire Inc.GeoVax Announces Multiple Patent Issuances and AllowancesNASDAQ:GOVXWGeoVax Labs Inc
06/02/202414:00GlobeNewswire Inc.GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine BoosterNASDAQ:GOVXWGeoVax Labs Inc
29/01/202414:00GlobeNewswire Inc.GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid RequirementNASDAQ:GOVXWGeoVax Labs Inc
08/01/202414:00GlobeNewswire Inc.GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, OncologyNASDAQ:GOVXWGeoVax Labs Inc
04/01/202414:00GlobeNewswire Inc.GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer PatientsNASDAQ:GOVXWGeoVax Labs Inc
03/01/202414:00GlobeNewswire Inc.GeoVax Announces Issuance of Malaria Vaccine PatentNASDAQ:GOVXWGeoVax Labs Inc
27/12/202314:00GlobeNewswire Inc.GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024NASDAQ:GOVXWGeoVax Labs Inc
19/12/202314:00GlobeNewswire Inc.GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and SmallpoxNASDAQ:GOVXWGeoVax Labs Inc
30/11/202321:30GlobeNewswire Inc.GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine CongressNASDAQ:GOVXWGeoVax Labs Inc
29/11/202314:00GlobeNewswire Inc.GeoVax to Participate in Upcoming December Investor EventsNASDAQ:GOVXWGeoVax Labs Inc
28/11/202314:00GlobeNewswire Inc.GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine CongressNASDAQ:GOVXWGeoVax Labs Inc
14/11/202314:00GlobeNewswire Inc.Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023NASDAQ:GOVXWGeoVax Labs Inc
 Showing the most relevant articles for your search:NASDAQ:GOVXW

Your Recent History

LSE
PANR
Pantheon Resources
LSE
LLOY
Lloyds Banking
LSE
GOLD
LSE
VAST
Vast Resources
LSE
BIRD
Blackbird
LSE
NEXN
Nexxen
LSE
ENET
Ethernity Networks
LSE
ARCM
Arc Minerals
LSE
NSCI
Netscientific
LSE
GMET
Golden Metal Resources
LSE
SBTX
Skinbiotherapeutics
LSE
LGEN
Legal & General
LSE
PHNX
Phoenix
LSE
HE1
Helium One Global
LSE
GNC
Greencore
LSE
GKP
Gulf Keystone Petroleum
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved